Chemotherapeutic Prevention of Choriocarcinoma Developed in Persistent Trophoblastic Disease after Hydatidiform Mole
Archives of Clinical Case Studies · 2019
DOI: 10.33552/accs.2019.01.000513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Clinical Case Studies, 2019. Verfasst von Kazuo Maeda.
Abstract (Originalsprache)
The author treated choriocarcinoma (Ch-C) with systemic primary Methotrexate (MTX) and achieved complete remission with the disappearance of primary and metastatic foci by repeated 200 to 300 mg intensive MTX courses, confirmed by the loss of human chorionic gnadotropine (hCG) in the serum and urine. Thus, the author intended to prevent choriocarcinoma (Ch-C) with MTX chemotherapy.
Zitieren
APA
Maeda, K. (2019). Chemotherapeutic Prevention of Choriocarcinoma Developed in Persistent Trophoblastic Disease after Hydatidiform Mole. Archives of Clinical Case Studies. https://doi.org/10.33552/accs.2019.01.000513
Vancouver
Maeda K. Chemotherapeutic Prevention of Choriocarcinoma Developed in Persistent Trophoblastic Disease after Hydatidiform Mole. Archives of Clinical Case Studies. 2019. doi:10.33552/accs.2019.01.000513
BibTeX
@article{Maeda2019,
author = {Maeda, Kazuo},
title = {Chemotherapeutic Prevention of Choriocarcinoma Developed in Persistent Trophoblastic Disease after Hydatidiform Mole},
journal = {Archives of Clinical Case Studies},
year = {2019},
doi = {10.33552/accs.2019.01.000513}
}
EUVIMED